Among these drugs, pharmacological inhibitors of the receptor-interacting serine/threonine protein kinase 1 (RIPK1) have entered clinical trials for the treatment of autoimmune diseases (psoriasis, ulcerative colitis and rheumatoid arthritis), as well as some cancers and neurological disorders (Mifflin et al., 2020). This evidence concerns the gene RIPK1 and psoriasis.